SCHEMBL1702965

SCHEMBL1702965

Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cncc21

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.79
KIT P10721 10/20 0.79
CSF1R P07333 9/20 0.79
FLT1 P17948 9/20 0.79
FLT3 P36888 9/20 0.79
FLT4 P35916 8/20 0.79
LCK P06239 7/20 0.79
LYN P07948 7/20 0.79
BLK P51451 7/20 0.79
MET P08581 5/20 0.79
FGFR1 P11362 5/20 0.79
RPS6KB1 P23443 5/20 0.79
EPHA2 P29317 5/20 0.79
CSNK1D P48730 5/20 0.79
RPS6KA3 P51812 5/20 0.79
ROCK1 Q13464 5/20 0.79
RET P07949 5/20 0.79
AURKB Q96GD4 4/20 0.79
DYRK3 O43781 4/20 0.79
ROCK2 O75116 4/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702967 0.88 KDR (1.00) KDRKITCSF1RFLT1FLT3
SCHEMBL1703583 0.86 KIT (1.00) KDRKITCSF1RFLT1FLT3
SCHEMBL1703600 0.85 KDR (0.78) KDRKITCSF1RFLT1FLT3
SCHEMBL3842668 0.84 KDR (0.59) KDRKITCSF1RFLT1FLT3
SCHEMBL1703074 0.83 KDR (0.78) KDRKITCSF1RFLT1FLT3
SCHEMBL14176156 0.83 KDR (0.58) KDRKITCSF1RFLT1FLT3
SCHEMBL1702841 0.83 KDR (0.78) KDRKITCSF1RFLT1FLT3
SCHEMBL1702785 0.82 KDR (0.76) KDRKITCSF1RFLT1FLT3
SCHEMBL2816193 0.82 KDR (0.58) KDRKITCSF1RFLT1FLT3
SCHEMBL3843405 0.81 KDR (0.56) KDRKITCSF1RFLT1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885KIT 426/4885CSF1R 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.